EX VIVO EXPANDED HUMAN Vλ9Vδ2+ λδ-T CELLS MEDIATE INNATE ANTITUMOR ACTIVITY AGAINST HUMAN PROSTATE CANCER CELLS IN VITRO

Ex vivo, expanded human Vλ9Vδ2+ λδ-T cells are able innately to recognize and kill certain human prostate tumor cell lines in vitro. The recognition and killing of prostate cancer cells occurs in a λδ-T-cell receptor dependent manner and it also appears to involve interactions between ICAM-1 and CD18. Because apoptosis resistant human Vλ9Vδ2+ λδ-T cells can readily be expanded to large numbers (clinical scale), these findings must be considered in the context of developing adoptive immunotherapy strategies to exploit λδ-T cell innate immune responses to prostate cancer.